HK1155172A1 - Amidophenoxyindazoles useful as inhibitors of c-met - Google Patents
Amidophenoxyindazoles useful as inhibitors of c-metInfo
- Publication number
- HK1155172A1 HK1155172A1 HK11109520.7A HK11109520A HK1155172A1 HK 1155172 A1 HK1155172 A1 HK 1155172A1 HK 11109520 A HK11109520 A HK 11109520A HK 1155172 A1 HK1155172 A1 HK 1155172A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- amidophenoxyindazoles
- inhibitors
- met
- useful
- amidophenoxyindazoles useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8329408P | 2008-07-24 | 2008-07-24 | |
| US8508208P | 2008-07-31 | 2008-07-31 | |
| US10865908P | 2008-10-27 | 2008-10-27 | |
| PCT/US2009/050640 WO2010011538A1 (en) | 2008-07-24 | 2009-07-15 | Amidophenoxyindazoles useful as inhibitors of c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1155172A1 true HK1155172A1 (en) | 2012-05-11 |
Family
ID=41010247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11109520.7A HK1155172A1 (en) | 2008-07-24 | 2011-09-08 | Amidophenoxyindazoles useful as inhibitors of c-met |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8030302B2 (ru) |
| EP (1) | EP2310382B1 (ru) |
| JP (1) | JP5414794B2 (ru) |
| KR (1) | KR101334456B1 (ru) |
| CN (1) | CN102105462B (ru) |
| AR (1) | AR074632A1 (ru) |
| AT (1) | ATE546444T1 (ru) |
| AU (1) | AU2009274256B2 (ru) |
| BR (1) | BRPI0916286B8 (ru) |
| CA (1) | CA2731773C (ru) |
| CL (1) | CL2011000134A1 (ru) |
| CO (1) | CO6351737A2 (ru) |
| CR (1) | CR20110046A (ru) |
| CY (1) | CY1112595T1 (ru) |
| DK (1) | DK2310382T3 (ru) |
| DO (1) | DOP2011000009A (ru) |
| EA (1) | EA018385B1 (ru) |
| EC (1) | ECSP11010778A (ru) |
| ES (1) | ES2379587T3 (ru) |
| HK (1) | HK1155172A1 (ru) |
| HR (1) | HRP20120202T1 (ru) |
| IL (1) | IL210490A (ru) |
| JO (1) | JO2788B1 (ru) |
| MA (1) | MA32594B1 (ru) |
| MX (1) | MX2011000925A (ru) |
| MY (1) | MY163852A (ru) |
| NZ (1) | NZ590013A (ru) |
| PE (1) | PE20110150A1 (ru) |
| PL (1) | PL2310382T3 (ru) |
| PT (1) | PT2310382E (ru) |
| RS (1) | RS52261B (ru) |
| SI (1) | SI2310382T1 (ru) |
| SV (1) | SV2011003816A (ru) |
| TW (1) | TWI365185B (ru) |
| WO (1) | WO2010011538A1 (ru) |
| ZA (1) | ZA201100219B (ru) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045095A1 (en) | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
| RU2011142597A (ru) | 2009-03-21 | 2013-04-27 | Саншайн Лейк Фарма Ко., Лтд. | Производные сложных эфиров аминокислот, их соли и способы применения |
| KR101546693B1 (ko) | 2011-02-28 | 2015-08-24 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 퀴놀린 화합물 및 그 사용 방법 |
| US8962623B2 (en) * | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| CA2869316C (en) * | 2012-05-09 | 2016-12-20 | Eli Lilly And Company | Anti-c-met antibodies |
| WO2014134313A1 (en) * | 2013-02-27 | 2014-09-04 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
| CN104140393B (zh) * | 2013-12-10 | 2016-09-21 | 郑州泰基鸿诺医药股份有限公司 | 一种芳环/芳杂环叔丁醇酯类化合物的制备方法 |
| JP6500037B2 (ja) | 2014-04-22 | 2019-04-10 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ | 二環式ピラゾロン化合物および使用方法 |
| TW201716085A (zh) * | 2015-08-12 | 2017-05-16 | 應克隆公司 | 癌症之組合療法 |
| EP3442573A1 (en) | 2016-04-15 | 2019-02-20 | Eli Lilly and Company | Combination of ramucirumab and merestinib for use in treatment of colorectal cancer |
| RU2766119C2 (ru) | 2016-06-02 | 2022-02-08 | Иммунокор Лимитед | Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv |
| JP2019525934A (ja) * | 2016-07-29 | 2019-09-12 | イーライ リリー アンド カンパニー | 癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療 |
| CN108069938A (zh) * | 2016-11-15 | 2018-05-25 | 中国药科大学 | 2,4-二取代吡啶类化合物及其制备方法和应用 |
| WO2018093654A1 (en) | 2016-11-16 | 2018-05-24 | Eli Lilly And Company | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
| EP3541383B1 (en) | 2016-11-16 | 2021-01-06 | Eli Lilly and Company | Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
| CN107311983A (zh) * | 2017-07-06 | 2017-11-03 | 北京万全德众医药生物技术有限公司 | 吲哚类小分子c‑met抑制剂 |
| CN107382968A (zh) * | 2017-07-06 | 2017-11-24 | 北京万全德众医药生物技术有限公司 | 一种吲哚类c‑Met抑制剂的制备方法 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| EP3480201A1 (en) | 2017-11-06 | 2019-05-08 | Oncostellae, S.L. | New analogs as androgen receptor and glucocorticoid receptor modulators |
| WO2019101178A1 (zh) | 2017-11-24 | 2019-05-31 | 南京明德新药研发股份有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| US20210177828A1 (en) * | 2018-01-17 | 2021-06-17 | Nanjing Transthera Biosciences Co., Ltd. | Tam family kinase /and csf1r kinase inhibitor and use thereof |
| EP3762392B1 (en) | 2018-03-08 | 2024-05-15 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| KR20210049862A (ko) * | 2018-08-24 | 2021-05-06 | 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 | 일종의 신형 퀴놀린 유도체 억제제 |
| US11952364B2 (en) | 2018-09-03 | 2024-04-09 | Tyligand Bioscience (Shanghai) Limited | TRK inhibitors useful as anticancer drugs |
| US20230172914A1 (en) | 2019-09-06 | 2023-06-08 | Wellmarker Bio Co., Ltd. | Biomarker-based therapeutic composition |
| WO2022270881A1 (ko) * | 2021-06-22 | 2022-12-29 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO155316C (no) * | 1982-04-23 | 1987-03-11 | Sintef | Fremgangsmaate for fremstilling av magnetiske polymerpartikler. |
| US5484681A (en) * | 1994-10-31 | 1996-01-16 | Xerox Corporation | Conductive composite particles and processes for the preparation thereof |
| IL114149A0 (en) * | 1995-06-14 | 1995-10-31 | Yeda Res & Dev | Modified avidin and streptavidin molecules and use thereof |
| US5747577A (en) * | 1995-12-27 | 1998-05-05 | Xerox Corporation | Conductive particles containing carbon black and processes for the preparation thereof |
| DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
| CN1258091C (zh) * | 2001-05-18 | 2006-05-31 | 爱赐爱儿股份有限公司 | 免疫测定 |
| US6956084B2 (en) * | 2001-10-04 | 2005-10-18 | Bridgestone Corporation | Nano-particle preparation and applications |
| JP2004067703A (ja) * | 2002-04-24 | 2004-03-04 | Japan Science & Technology Corp | 架橋ポリマー、微粒子および製造方法 |
| US7192780B2 (en) * | 2002-10-23 | 2007-03-20 | Evident Technologies | Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals |
| CA2503646C (en) | 2002-10-28 | 2011-09-27 | Bayer Healthcare Ag | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
| WO2005015216A1 (en) * | 2003-07-17 | 2005-02-17 | Dynal Biotech Asa | Process for preparing coated magnetic particles |
| US7163998B2 (en) * | 2003-09-09 | 2007-01-16 | Eastman Kodak Company | Stabilized polymer beads and method of preparation |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
| CA2645137A1 (en) * | 2006-03-07 | 2007-09-13 | James F. Blake | Heterobicyclic pyrazole compounds and methods of use |
| EP2230264B1 (en) * | 2006-06-29 | 2019-10-09 | Life Technologies AS | Particles containing multi-block polymers |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| JP5378222B2 (ja) | 2006-10-23 | 2013-12-25 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | タンパク質キナーゼ調節物質としての二環式トリアゾール |
| KR101550250B1 (ko) | 2007-06-27 | 2015-09-04 | 알케마 인코포레이티드 | 하이드로플루오로올레핀의 제조 방법 |
-
2009
- 2009-07-10 TW TW098123519A patent/TWI365185B/zh not_active IP Right Cessation
- 2009-07-12 JO JO2009256A patent/JO2788B1/en active
- 2009-07-13 AR ARP090102636A patent/AR074632A1/es active IP Right Grant
- 2009-07-15 PL PL09790440T patent/PL2310382T3/pl unknown
- 2009-07-15 CN CN200980128694.4A patent/CN102105462B/zh not_active Expired - Fee Related
- 2009-07-15 PE PE2011000061A patent/PE20110150A1/es active IP Right Grant
- 2009-07-15 US US12/503,223 patent/US8030302B2/en not_active Ceased
- 2009-07-15 JP JP2011520095A patent/JP5414794B2/ja not_active Expired - Fee Related
- 2009-07-15 EA EA201170252A patent/EA018385B1/ru not_active IP Right Cessation
- 2009-07-15 DK DK09790440.3T patent/DK2310382T3/da active
- 2009-07-15 MY MYPI2011000343A patent/MY163852A/en unknown
- 2009-07-15 WO PCT/US2009/050640 patent/WO2010011538A1/en active Application Filing
- 2009-07-15 RS RS20120176A patent/RS52261B/en unknown
- 2009-07-15 KR KR1020117001628A patent/KR101334456B1/ko active IP Right Grant
- 2009-07-15 BR BRPI0916286A patent/BRPI0916286B8/pt not_active IP Right Cessation
- 2009-07-15 PT PT09790440T patent/PT2310382E/pt unknown
- 2009-07-15 AU AU2009274256A patent/AU2009274256B2/en not_active Ceased
- 2009-07-15 AT AT09790440T patent/ATE546444T1/de active
- 2009-07-15 NZ NZ590013A patent/NZ590013A/en not_active IP Right Cessation
- 2009-07-15 SI SI200930193T patent/SI2310382T1/sl unknown
- 2009-07-15 EP EP09790440A patent/EP2310382B1/en active Active
- 2009-07-15 ES ES09790440T patent/ES2379587T3/es active Active
- 2009-07-15 MX MX2011000925A patent/MX2011000925A/es active IP Right Grant
- 2009-07-15 CA CA2731773A patent/CA2731773C/en not_active Expired - Fee Related
-
2011
- 2011-01-06 IL IL210490A patent/IL210490A/en active IP Right Grant
- 2011-01-07 ZA ZA2011/00219A patent/ZA201100219B/en unknown
- 2011-01-07 DO DO2011000009A patent/DOP2011000009A/es unknown
- 2011-01-19 CO CO11005437A patent/CO6351737A2/es not_active Application Discontinuation
- 2011-01-21 CL CL2011000134A patent/CL2011000134A1/es unknown
- 2011-01-21 EC EC2011010778A patent/ECSP11010778A/es unknown
- 2011-01-21 SV SV2011003816A patent/SV2011003816A/es active IP Right Grant
- 2011-01-24 CR CR20110046A patent/CR20110046A/es unknown
- 2011-01-24 MA MA33555A patent/MA32594B1/fr unknown
- 2011-09-08 HK HK11109520.7A patent/HK1155172A1/xx not_active IP Right Cessation
- 2011-12-08 US US13/374,053 patent/USRE43878E1/en not_active Expired - Fee Related
-
2012
- 2012-03-01 HR HR20120202T patent/HRP20120202T1/hr unknown
- 2012-04-04 CY CY20121100337T patent/CY1112595T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI365185B (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
| HK1223272A1 (zh) | 程序性壞死的小分子抑制劑 | |
| HK1156306A1 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4- | |
| HRP20130787T1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| HRP20130698T1 (en) | Novel phenylpyrazinones as kinase inhibitors | |
| ZA201104749B (en) | Benzonaphtyridine compounds used as inhibitors of autotaxin | |
| IL207100A0 (en) | 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace) | |
| GB0621607D0 (en) | Inhibitors of c-Met | |
| EP2249650A4 (en) | ANILINOPYRIDINE AS A FAK HEMMER | |
| ZA201100898B (en) | Novel inhibitors | |
| ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
| HK1161680A1 (en) | Pyrazolylaminopyridines as inhibitors of fak fak | |
| PT2297115E (pt) | Derivados de quinazolina | |
| PL2133419T3 (pl) | Zastosowania beta-dipeptydów cyjanoficyny | |
| HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
| IL208916A0 (en) | Inhibitors of jnk | |
| EP2382974A4 (en) | USE OF CYCLOSQUARAMIDE COMPOUNDS AS ANTITUMOR AGENTS | |
| GB0821710D0 (en) | Derivatives of dihydroindolone | |
| PL386302A1 (pl) | Nowa pochodna izotiazolopirydyny | |
| GB0816125D0 (en) | Novel inhibitors | |
| GB0621980D0 (en) | Inhibitors of c-Met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210713 |